Alzamend Neuro, Inc.
ALZN
$2.96
-$0.03-1.00%
NASDAQ
04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 688.80K | 590.30K | 1.05M | 755.80K | 666.60K |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 1.14M | 1.04M | 1.36M | 962.40K | 850.10K |
Operating Income | -1.14M | -1.04M | -1.36M | -962.40K | -850.10K |
Income Before Tax | -1.14M | -1.04M | -1.36M | -974.40K | -851.50K |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -1.14M | -1.04M | -1.36M | -974.40K | -851.50K |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -1.14M | -1.04M | -1.36M | -974.40K | -851.50K |
EBIT | -1.14M | -1.04M | -1.36M | -962.40K | -850.10K |
EBITDA | -1.13M | -1.02M | -1.35M | -949.70K | -837.40K |
EPS Basic | -2.43 | -1.70 | -3.61 | -11.27 | -11.14 |
Normalized Basic EPS | -1.00 | -1.06 | -2.17 | -7.05 | -6.96 |
EPS Diluted | -2.43 | -1.70 | -3.61 | -11.27 | -11.14 |
Normalized Diluted EPS | -1.00 | -1.06 | -2.17 | -7.05 | -6.96 |
Average Basic Shares Outstanding | 711.30K | 613.10K | 392.40K | 86.40K | 76.50K |
Average Diluted Shares Outstanding | 711.30K | 613.10K | 392.40K | 86.40K | 76.50K |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |